New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota

Biomolecules

Marina Lorente-Picón¹  Ariadna Laguna¹ 

[1] Neurodegenerative Diseases Research Group, Vall d’Hebron Institut de Recerca (VHIR)-Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain;

关键词: Parkinson’s disease;    gut microbiota;    therapeutic modulation;    gut–brain axis;    prebiotics;    probiotics;   

DOI  :  10.3390/biom11030433

来源: DOAJ

【 摘 要 】

Parkinson’s disease (PD) is a multifactorial neurodegenerative disorder that currently affects 1% of the population over the age of 60 years, and for which no disease-modifying treatments exist. Neurodegeneration and neuropathology in different brain areas are manifested as both motor and non-motor symptoms in patients. Recent interest in the gut–brain axis has led to increasing research into the gut microbiota changes in PD patients and their impact on disease pathophysiology. As evidence is piling up on the effects of gut microbiota in disease development and progression, another front of action has opened up in relation to the potential usage of microbiota-based therapeutic strategies in treating gastrointestinal alterations and possibly also motor symptoms in PD. This review provides status on the different strategies that are in the front line (i.e., antibiotics; probiotics; prebiotics; synbiotics; dietary interventions; fecal microbiota transplantation, live biotherapeutic products), and discusses the opportunities and challenges the field of microbiome research in PD is facing.

【 授权许可】

Unknown